๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

Short form of the heparin-binding EGF-like growth factor: Communication II

โœ Scribed by E. V. Loukianov; Yu. V. Kozlov


Book ID
110174386
Publisher
SP MAIK Nauka/Interperiodica
Year
2006
Tongue
English
Weight
242 KB
Volume
40
Category
Article
ISSN
0026-8933

No coin nor oath required. For personal study only.


๐Ÿ“œ SIMILAR VOLUMES


The chemical synthesis and binding affin
โœ Song Yub Shin; Tetsuo Yokoyama; Takato Takenouchi; Eisuke Munekata ๐Ÿ“‚ Article ๐Ÿ“… 2003 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 125 KB

## Abstract Heparinโ€binding EGFโ€like growth factor (HBโ€EGF), which belongs to the EGFโ€family of growth factors, was isolated from the conditioned medium of macrophageโ€like cells. To investigate the effect of __N__โ€ and __C__โ€terminal residues of the EGFโ€like domain of HBโ€EGF in the binding affinity

High expression of heparin-binding EGF-l
โœ Eiji Miyoshi; Shigeki Higashiyama; Takatoshi Nakagawa; Keiichiro Suzuki; Masayos ๐Ÿ“‚ Article ๐Ÿ“… 1996 ๐Ÿ› John Wiley and Sons ๐ŸŒ French โš– 511 KB

Heparin-binding epidermal growth factor (EGF)-like growth factor (HB-EGF) is a member of the EGF family and is highly expressed in hepatoma tissues but not in normal liver. However, it is unknown when HB-EGF is induced during hepatocarcinogenesis and what are the mechanisms underlying its high expre

Co-expression of heparin-binding EGF-lik
โœ Markus Naef; Munehiro Yokoyama; Helmut Friess; Markus W. Bรผchler; Murray Korc ๐Ÿ“‚ Article ๐Ÿ“… 1996 ๐Ÿ› John Wiley and Sons ๐ŸŒ French โš– 898 KB

Heparin-binding epidermal growth factor (EGF)-like growth factor (HB-EGF) is a member of the EGF family of polypeptide growth factors, which includes EGF, transforming growth faaor a (TGF-a), amphiregulin (AR) and betacellulin (BTC). To assess the potential role of HB-EGF in human gastric carcinomas

Induction of heparin-binding EGF-like gr
โœ Faye M. Johnson; Babita Saigal; Nicholas J. Donato ๐Ÿ“‚ Article ๐Ÿ“… 2005 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 459 KB

Imatinib mesylate is a tyrosine kinase inhibitor of the ABL, platelet-derived growth factor receptor (PDGFR), and c-kit kinases. Inhibition of BCR-ABL and c-kit accounts for its clinical activity in leukemia and sarcoma, respectively. In this report, we describe other cellular targets for imatinib.